Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer.
Neeb A, Figueiredo I, Gurel B, Nava Rodrigues D, Rekowski J, Riisnaes R, Ferreira A, Miranda S, Crespo M, Westaby D, de Los Dolores Fenor de La Maza M, Guo C, Carmichael J, Grochot R, Tunariu N, Cato ACB, Plymate SR, de Bono JS, Sharp A. Neeb A, et al. Among authors: gurel b. Lab Invest. 2023 Nov;103(11):100245. doi: 10.1016/j.labinv.2023.100245. Epub 2023 Aug 29. Lab Invest. 2023. PMID: 37652207 Free article.
A Transgender Patient with Prostate Cancer: Lessons Learnt.
Chandran K, Grochot R, de Los Dolores Fenor De La Maza M, Yuan W, Gurel B, Miranda S, Paschalis A, Riisnaes R, Figueiredo I, Bogdan D, Sharp A, Carreira S, de Bono JS. Chandran K, et al. Among authors: gurel b. Eur Urol. 2023 Apr;83(4):379-380. doi: 10.1016/j.eururo.2022.12.027. Epub 2023 Jan 4. Eur Urol. 2023. PMID: 36609007 No abstract available.
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer.
Bancaro N, Calì B, Troiani M, Elia AR, Arzola RA, Attanasio G, Lai P, Crespo M, Gurel B, Pereira R, Guo C, Mosole S, Brina D, D'Ambrosio M, Pasquini E, Spataro C, Zagato E, Rinaldi A, Pedotti M, Di Lascio S, Meani F, Montopoli M, Ferrari M, Gallina A, Varani L, Pereira Mestre R, Bolis M, Gillessen Sommer S, de Bono J, Calcinotto A, Alimonti A. Bancaro N, et al. Among authors: gurel b. Cancer Cell. 2023 Mar 13;41(3):602-619.e11. doi: 10.1016/j.ccell.2023.02.004. Epub 2023 Mar 2. Cancer Cell. 2023. PMID: 36868226 Free article.
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38].
Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, Carreira S, Rekowski J, Buroni L, Welti J, Bogdan D, Gallagher L, Sharp A, de la Maza MDF, Rescigno P, Westaby D, Chandran K, Riisnaes R, Ferreira A, Miranda S, Calì B, Alimonti A, Bressan S, Nguyen AHT, Shen MM, Hawley JE, Obradovic A, Drake CG, Bertan C, Baker C, Tunariu N, Yuan W, de Bono JS. Guo C, et al. Among authors: gurel b. Eur Urol. 2023 Jun;83(6):e168-e169. doi: 10.1016/j.eururo.2023.03.005. Epub 2023 Mar 22. Eur Urol. 2023. PMID: 36964041 Free article. No abstract available.
Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer.
Grochot R, Carreira S, Miranda S, Figueiredo I, Bertan C, Rekowski J, Yuan W, Ferreira A, Riisnaes R, Neeb A, Gurel B, de Los Dolores Fenor de la Maza M, Guo C, Carmichael J, Westaby D, Mateo J, Sharp A, McVeigh TP, De Bono J. Grochot R, et al. Among authors: gurel b. Eur Urol Open Sci. 2023 May 2;52:72-78. doi: 10.1016/j.euros.2023.04.003. eCollection 2023 Jun. Eur Urol Open Sci. 2023. PMID: 37284046 Free PMC article.
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Rescigno P, Porta N, Finneran L, Riisnaes R, Figueiredo I, Carreira S, Flohr P, Miranda S, Bertan C, Ferreira A, Crespo M, Rodrigues DN, Gurel B, Nobes J, Crabb S, Malik Z, Ralph C, McGovern U, Hoskin P, Jones RJ, Birtle A, Gale J, Sankey P, Jain S, McLaren D, Chadwick E, Espinasse A, Hall E, de Bono J. Rescigno P, et al. Among authors: gurel b. Eur J Cancer. 2024 Jul;205:114103. doi: 10.1016/j.ejca.2024.114103. Epub 2024 May 8. Eur J Cancer. 2024. PMID: 38729054 Free PMC article. Clinical Trial.
RNASEH2B loss and PARP inhibition in advanced prostate cancer.
Carmichael J, Figueiredo I, Gurel B, Beije N, Yuan W, Rekowski J, Seed G, Carreira S, Bertan C, Fenor de La Maza MLD, Chandran K, Neeb A, Welti J, Gallagher L, Bogdan D, Crespo M, Riisnaes R, Ferreira A, Miranda S, Lu J, Shen MM, Hall E, Porta N, Westaby D, Guo C, Grochot R, Lord CJ, Mateo J, Sharp A, de Bono J. Carmichael J, et al. Among authors: gurel b. J Clin Invest. 2024 Jun 4;134(21):e178278. doi: 10.1172/JCI178278. J Clin Invest. 2024. PMID: 38833311 Free PMC article. Clinical Trial.
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy.
Al-Janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, de Bono J, Nunns H, Bailey C, Junker-Jensen A, Muthana M, Phillips WA, Pearson HB, Taplin ME, Brown JE, Lewis CE. Al-Janabi H, et al. Among authors: gurel b. J Immunother Cancer. 2024 Jul 25;12(7):e009368. doi: 10.1136/jitc-2024-009368. J Immunother Cancer. 2024. PMID: 39060021 Free PMC article.
Corrigendum to "Unbiased differential proteomic profiling between cancer-associated fibroblasts and cancer cell lines" [Journal of Proteomics (2023) Volume 288, Article number 104973].
Lau R, Yu L, Roumeliotis TI, Stewart A, Pickard L, Riisanes R, Gurel B, de Bono JS, Choudhary JS, Banerji U. Lau R, et al. Among authors: gurel b. J Proteomics. 2024 Oct 30;309:105306. doi: 10.1016/j.jprot.2024.105306. Epub 2024 Sep 6. J Proteomics. 2024. PMID: 39243748 Free article. No abstract available.
106 results